Deal facts
- Buyer
- OTPP
- Target
- DONTE GROUP
- Deal value
- Not disclosed
- Announced
- 22 July 2025
- Status
- In review
- Sector
- Healthcare
- Country
- Not stated
- Consideration
- Not stated
Sources
OTPP has agreed to acquire Donte Group in a transaction announced on 22 July 2025. The deal concerns a business operating within the NaceV2Sector_R_86.23 classification, which relates to other human health activities. No specific financial consideration or deal value has been disclosed to the public at this stage. The target country for the acquisition remains unreported in the available records.
The transaction is currently subject to regulatory approval and is listed as being in review. No completion date has been confirmed as the process continues. The management team has not yet executed a buyout or buy-in arrangement, and the specific structure of the deal remains undefined in the current data set. Further details regarding the final terms or the specific operational integration plans are not available for this summary.
Weekly digest
Join Exit Mode Insider
Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.
Join Exit Mode Insider, £12/moDeal timeline
1 update- CMA invitation to comment
OTPP to acquire DONTE GROUP
OTPP to acquire DONTE GROUP
EU DG COMP
Explore
Browse adjacent archives
Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.
Similar deals
Similar deals
Other Healthcare M&A activity tracked by Exit Mode.
KOHLBERG / MONTAGU to acquire TELEFLEX OEM BUSINESS
KOHLBERG / MONTAGU has agreed to acquire the TELEFLEX OEM Business in a transaction announced on 22 March 2026. The deal involves a company operating within the NaceV2Se…
- Buyer
- KOHLBERG / MONTAGU
- Target
- TELEFLEX OEM BUSINESS
- Deal value
- Not disclosed
- Deal type
- unknown
SK CAPITAL to acquire SWIXX BIOPHARMA
SK CAPITAL has agreed to acquire SWIXX BIOPHARMA in a transaction announced on 8 March 2026. The deal involves the biopharmaceutical sector, specifically within the whol…
- Buyer
- SK CAPITAL
- Target
- SWIXX BIOPHARMA
- Deal value
- Not disclosed
- Deal type
- unknown
EQT to acquire Oxford Biomedica plc
EQT has agreed to acquire Oxford Biomedica plc, a UK-based CDMO and viral vector specialist, in a transaction announced on 25 February 2026. The specific financial terms…
- Buyer
- EQT
- Target
- Oxford Biomedica plc
- Deal value
- Not disclosed
- Deal type
- unknown
GTCR to acquire ZENTIVA
GTCR has agreed to acquire ZENTIVA in a transaction announced on 19 February 2026. The deal involves the pharmaceutical sector, classified under NaceV2Sector_C_21. No fi…
- Buyer
- GTCR
- Target
- ZENTIVA
- Deal value
- Not disclosed
- Deal type
- unknown
WARBURG PINCUS to acquire SEBIA
WARBURG PINCUS has agreed to acquire SEBIA in a transaction announced on 12 November 2025. The deal involves a company operating across multiple industrial sectors, incl…
- Buyer
- WARBURG PINCUS
- Target
- SEBIA
- Deal value
- Not disclosed
- Deal type
- unknown
Buyer history
OTPP
See every published Exit Mode archive entry where this buyer appears.
View buyer profileMethodology
How this page is built
Layer 1 facts come from source documents, Layer 2 turns those facts into a readable narrative, and Layer 3 only appears where the editorial team flags a founder-relevant deal.
Back to the archive